Centrosome amplification as a possible marker of mitotic disruptions and cellular carcinogenesis in multiple myeloma

Leuk Res. 2010 Aug;34(8):1007-11. doi: 10.1016/j.leukres.2009.12.018. Epub 2010 Jan 21.

Abstract

Centrosome amplification (CA) as a potential marker of mitotic disruptions in multiple myeloma (MM) was investigated in two populations of B-cell lineage: B-cells and plasma cells (PCs). Using immunofluorescent staining, it was shown that CA in B-cells is present in 3.2+/-2.5% in healthy donors versus 9.9+/-7.9% in MM patients (p<0.0001). Based on the calculated threshold value of CA in B-cells, 37% (14/38) of MM patients were positive. There was no significant correlation between CA-positive MM cases (based on PC samples evaluation) and the occurrence of cytogenetic abnormalities in PCs, including del(13)(q14), del(17)(p13), gain(1)(q21) and hyperdiploidy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • B-Lymphocytes / metabolism
  • B-Lymphocytes / pathology*
  • Centrosome / metabolism*
  • Centrosome / pathology
  • Female
  • Fluorescent Antibody Technique
  • Humans
  • In Situ Hybridization, Fluorescence
  • Karyotyping
  • Male
  • Middle Aged
  • Mitosis*
  • Multiple Myeloma / genetics*
  • Multiple Myeloma / pathology*
  • Plasma Cells / metabolism
  • Plasma Cells / pathology*
  • Prognosis